Long is the medical director of Melanoma Institute Australia (MIA), and chair of melanoma medical oncology and translational research at MIA and Royal North Shore Hospital, The University of Sydney.
March 27, 2025
Video
The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.
This Wasn’t the Plan: I Lost My Hair, Not My Fire
Social and Economic Barriers May Affect Outcomes in Blood Cancers
Survival, Symptoms and Support in Waldenström Macroglobulinemia
Therapies Which Received FDA Approval in July: What Patients Should Know